ERYP Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2023 @ 22:48):

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States...

Stats
Dzisiejszy wolumen	3 205.00
Średni wolumen	148 586
Kapitalizacja rynkowa	47.38M
EPS	$0 ( 2023-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-78.00
ATR14	$0.108 (13.85%)

Wolumen Korelacja

Długi: 0.13 (neutral)

Krótki: -0.16 (neutral)

Signal:(42.503) Neutral

Erytech Pharma S.A. Korelacja

10 Najbardziej pozytywne korelacje
DGHI	0.897
ITMR	0.884
AVEO	0.874
SOHON	0.868
CHDN	0.859
DVCR	0.851
SOHOB	0.848
XLO	0.847
BTBT	0.846
KIN	0.846

10 Najbardziej negatywne korelacje
AMRB	-0.873
SABS	-0.861
ORRF	-0.857
VTIP	-0.857
TRIB	-0.846
POLA	-0.837
SGMA	-0.833
SOPA	-0.816
MMAC	-0.814
LFMD	-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Erytech Pharma S.A. Korelacja - Waluta/Towar

-0.24
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.17
( neutral )

0.72
( moderate )

0.11
( neutral )

Erytech Pharma S.A. Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.00740

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.00740

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.68

FY	2020
Przychody:	$0.00
Zysk brutto:	$-57.58M (0.00 %)
EPS:	$-3.65

Financial Reports:

No articles found.

Erytech Pharma S.A.

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.